As many know in the industry, Vasomedical EECP was evaluated by the ACC and AHA Guidelines for the Classification and Level of Evidence for the treatment of Stable Ischemic Heart Disease. While many may believe there is substantial evidence for External Counterpulsation Therapy to have a higher classification for the treatment of symptomatic heart disease, the ACC / AHA task force retained its classification of Class IIb and Level of Evidence rating B. This retaining of its classification comes at a time of great change in the Healthcare Industry (particularly in Cardiology), many find the results of the new guidelines to be a great success.
Regardless of what perspective one sees by the outcome, one thing in particular stood out that is worth mentioning. The mention of the trademarked term EECP to somehow rule out other brands of ECP devices as a the only brand to fit this category is a serious exaggeration. Lets take a closer look:
Although driving two different nascar’s at the Indy 500, I think most would agree that the performance between each motorcar is almost nothing. It is more up to the driver that creates the outcome than the actual car itself. And this most know that the outcomes for patient with Stable Ischemic Heart Disease will be more or less the same if the treatment variable were identical.
Most External Counterpulsation Therapy devices have the capability to inflate and deflate at the same timing sequence as well as achieving the same level of pressures. The outcomes in treatment on virtually any device is more dependent on the attention of the therapist as it is the actual device much like Nascar. This is just common sense!
For more information about EECP and ECP Therapy, visit our comparison EECP vs ECP Therapy
